Members may have seen earlier reports that Mylan Australia would be supplying a generic version of EpiPen® without the EpiPen® brand name and also that Link Healthcare would be supplying Emerade® adrenaline autoinjectors in Australia. This was in response to an EpiPen® shortage in Australia.
Mylan has just announced that there is no longer a need for these products as EpiPen® stock levels have recovered. The Therapeutic Goods Administration will not be proceeding with authorisation of Emerade® for sale in Australia. It appears that manufacturers of adrenaline (epinephrine) autoinjectors regard the Australian market as too small to accommodate multiple brands.
New 2018 versions of ASCIA Action Plans are now available HERE.